These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19517317)

  • 1. Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.
    Mucke HA
    IDrugs; 2009 Jun; 12(6):366-75. PubMed ID: 19517317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.
    Price LC; Howard LS
    Am J Cardiovasc Drugs; 2008; 8(3):171-85. PubMed ID: 18533738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Langleben D
    Clin Chest Med; 2007 Mar; 28(1):117-25, viii. PubMed ID: 17338931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
    Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
    Shetty N; Derk CT
    Inflamm Allergy Drug Targets; 2011 Feb; 10(1):19-26. PubMed ID: 21184655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.
    Rubin LJ
    Life Sci; 2012 Oct; 91(13-14):517-21. PubMed ID: 22884806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pulmonary hypertension and right ventricular failure. Part XI. Endothelin receptor blockers in the treatment of primary pulmonary arterial hypertension].
    Batyraliev TA; Makhmutkhodzhaev SA; Ekinsi E; Pataraia SA; Pershukov IV; Sidorenko BA; Preobrazhenskiĭ DV
    Kardiologiia; 2007; 47(7):73-82. PubMed ID: 18260899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
    Hoeper MM
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S308-10. PubMed ID: 17139593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Endothelin-receptor antagonists in therapy of pulmonary arterial hypertension].
    Ghofrani HA
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S177-8. PubMed ID: 19718611
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].
    Cacoub P; Amoura Z; Langleben D
    Rev Med Interne; 2008 Apr; 29(4):283-9. PubMed ID: 18243424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.
    Vizza CD; Fedele F; Pezzuto B; Rubin LJ
    Expert Opin Drug Saf; 2012 Nov; 11(6):1003-11. PubMed ID: 22861496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P; Coghlan G
    Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials].
    Macías Saint-Gerons D; de la Fuente Honrubia C; Montero Corominas D; Catalá-López F
    Med Clin (Barc); 2014 Apr; 142(8):333-42. PubMed ID: 23540381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
    Opitz CF; Ewert R; Kirch W; Pittrow D
    Eur Heart J; 2008 Aug; 29(16):1936-48. PubMed ID: 18562303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.
    Steiner MK; Preston IR
    Vasc Health Risk Manag; 2008; 4(5):943-52. PubMed ID: 19183742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].
    Montani D; Humbert M
    Rev Mal Respir; 2010 Feb; 27(2):103-5. PubMed ID: 20206056
    [No Abstract]   [Full Text] [Related]  

  • 17. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension.
    Kim NH; Rubin LJ
    J Cardiovasc Pharmacol Ther; 2002 Jan; 7(1):9-19. PubMed ID: 12000973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin receptor antagonists in pulmonary arterial hypertension.
    Dupuis J; Hoeper MM
    Eur Respir J; 2008 Feb; 31(2):407-15. PubMed ID: 18238950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transitioning between endothelin receptor blockers: monitoring to ensure a smooth transition.
    Luo N; Ryan JJ
    Can J Cardiol; 2013 Jun; 29(6):659-61. PubMed ID: 22985784
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases.
    Humbert M; Simonneau G
    Nat Clin Pract Rheumatol; 2005 Dec; 1(2):93-101. PubMed ID: 16932638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.